Alpha Cognition announces top-line data in BEACON study for Alzheimer’s

Alpha Cognition has reported positive top line data from the BEACON real-world study assessing provider-reported outcomes for mild-to-moderate Alzheimer’s disease treated with Zunveyl. The study involved assessing patients for three to 12 months with Zunveyl after prior treatment or discontinuation. Reported outcomes included delayed initiation or discontinuation of additional psychotropic medications in 80% of patients. Credit: NMK-Studio / Shutterstock.com. Alpha Cognition has reported positive top line data from the BEACON real-world study assessing provider-reported outcomes for long-term care residents with mild-to-moderate Alzheimer’s disease treated with Zunveyl. The Phase IV, observational real-world study results are based on retrospective provider assessments and…

Source: Clinical Trials Arena